Ever Supreme Bio Technology , Ltd Profit Margin

The latest profit margin for 6712.TWO is 43.77% as of June 2026. That compares with 41.16% in the prior-year period — up 6.3% year over year. That is above the Healthcare sector average of 10.58%. Investors often review this figure alongside Ever Supreme Bio Technology , Ltd's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6712.TWO's profit margin moved from 41.16% to 43.77% — a 6.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ever Supreme Bio Technology , Ltd's valuation or profitability profile.

Against Healthcare companies, 6712.TWO currently prints 43.77% for profit margin, while the sector average sits near 10.58%. That is roughly 313.7% above the sector mean. Large gaps often invite a closer look at Ever Supreme Bio Technology , Ltd's growth, margins, and balance sheet.

Profit Margin shows how effectively Ever Supreme Bio Technology , Ltd converts resources into returns. At 43.77%, 6712.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 41.16% in the prior-year period — up 6.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 6712.TWO's profit margin (43.77%), review year-over-year change from 41.16%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.